The source combines proposed treatment schedules with findings from earlier studies and unpublished clinical experience. It describes the use of 20% Intralipid, intravenous immunoglobulin and corticosteroids, including doses, infusion timing and monitoring. These are proposed protocols rather than the results of a new controlled trial.

Intralipid is a soybean oil-based lipid emulsion described as suppressing natural killer-cell cytotoxicity and pro-inflammatory cytokine production. The proposed indication is an elevated proportion or absolute count of cytotoxic CD3–CD16+CD56+ natural killer cells or CD3+CD16+CD56+ natural killer T cells alongside spontaneous miscarriage, recurrent pregnancy loss, recurrent implantation failure, failed intrauterine insemination or inability to conceive.

The protocol recommends 50–200 mL of 20% Intralipid diluted in 250–500 mL of saline for slow intravenous infusion, with the dose adjusted to the degree of natural killer-cell elevation. In selected cases, prednisolone at 5–10 mg may begin about one week before ovulation or embryo transfer and continue until pregnancy testing. After a positive test, further Intralipid infusions may be given during weeks 3, 5 and 9 of amenorrhea, but only after follow-up testing confirms an elevation in the specified natural killer-cell population.

Available evidence remains limited and inconsistent. A retrospective study of 187 women with unexplained recurrent reproductive failure included 26 treated with Intralipid. Among 10 treated women with recurrent miscarriage, seven had live births, compared with significantly lower rates among untreated controls. Of 16 treated women with recurrent implantation failure, nine achieved clinical pregnancy and five of those pregnancies resulted in live birth. The small, selected treatment group and absence of identified distinguishing factors limit interpretation.

A 2020 systematic review screened 1,025 studies and included seven. A meta-analysis of nonrandomized intravenous immunoglobulin studies involving 557 participants favored treatment for live birth, with a risk ratio of 2.57 and p<0.05, but the studies had substantial heterogeneity and a moderate-to-severe risk of bias. Individual randomized trials reported favorable results for etanercept, Intralipid and prednisolone, with statistical significance for etanercept and Intralipid, although the source notes continuing controversy over Intralipid effectiveness.

Guidelines do not establish routine use. The source reports that the UK Human Fertilisation and Embryology Authority rates intravenous immunoglobulin and corticosteroids as interventions for which clinical benefit has not been established, while the American Society for Reproductive Medicine found insufficient evidence for intravenous immunoglobulin in IVF. The European Society of Human Reproduction and Embryology guideline on recurrent pregnancy loss does not support routine natural killer-cell testing or standard immunomodulatory treatment.

Safety and implementation also require caution. Reported Intralipid complications include hypersensitivity, infusion symptoms, hyperlipidemia and rare fat overload syndrome, particularly in people with impaired lipid metabolism or hepatic dysfunction. Corticosteroids carry risks that increase with dose and duration, including glucose intolerance, hypertension, infection susceptibility, mood changes, osteoporosis and adrenal suppression. Variation in doses, lack of standardized immune biomarkers and limited high-quality evidence complicate comparisons among protocols.

Subject of Research: Proposed clinical protocols for immunomodulation with Intralipid and corticosteroids in reproductive failure

Article Title: Immunomodulatory treatment protocols with Intralipid and corticosteroids for patients with reproductive failure: Clinical protocols

Article References: Velikova, T., Kokudeva, M., Mihova, A., Angelova, A., & Pencheva, B. (2026). Immunomodulatory treatment protocols with Intralipid and corticosteroids for patients with reproductive failure: Clinical protocols. Pharmacia, 73, Article e168168. https://doi.org/10.3897/pharmacia.73.e168168

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e168168

Keywords: Intralipid, reproductive immunology, infertility, recurrent pregnancy loss, recurrent implantation failure, natural killer cells, corticosteroids, IVIG, IVF, clinical protocol, Immunomodulatory, treatment

Kawasaki disease is an inflammatory condition of childhood that can damage the coronary arteries if left untreated. Standard therapy is intravenous immunoglobulin, or IVIG, but roughly one in ten children fails to respond to this treatment and faces a higher risk of serious cardiac complications. Identifying these children early matters enormously, because clinicians can escalate therapy before irreversible damage occurs. Over the past decade, research groups have built statistical and machine learning models to flag IVIG-resistant cases using routinely collected clinical and laboratory data, and several such models have reported promising accuracy in their original datasets.

The new study, led by Hongbiao Huang and colleagues across hospitals in Fujian and Jiangsu provinces in China, set out to answer a question that has received surprisingly little attention in pediatric medicine: what happens to a prediction model after it is deployed? Clinical prediction models are typically developed on historical data and then assumed to remain valid indefinitely. But the patients, the laboratory methods, the treatment protocols, and even the circulating pathogens that shape disease presentation all change over time. This phenomenon, known as temporal drift, can erode a model’s performance in ways that go unnoticed unless performance is actively monitored.

To investigate, the team assembled a retrospective cohort of 6,443 children with Kawasaki disease treated between 2006 and 2024 at multiple centers. They divided the cohort into three eras: a pre-COVID period from 2006 to 2019 with 3,788 children, a during-COVID period from 2020 to 2022 with 1,837 children, and an after-COVID period from 2023 to 2024 with 818 children. The proportion of children who developed IVIG resistance varied dramatically across these eras, at 7.0 percent, 13.9 percent, and 10.1 percent respectively. This shift in the underlying rate of resistance, known as case-mix change, is precisely the kind of drift that can destabilize a prediction model.

The researchers compared five machine learning algorithms, including logistic regression with LASSO regularization, support vector machines, and random forests, and selected the random forest model for deeper analysis. When the model developed on pre-COVID data was tested on later cohorts, its performance deteriorated markedly. The area under the receiver operating characteristic curve, or AUC, a standard measure of how well a model separates resistant from responsive patients, fell from 0.776 during the COVID era to just 0.629 after COVID. A value of 0.5 would represent no discrimination at all, so a drop of this magnitude means the model was barely better than chance in the most recent period.

Just as concerning was the collapse in calibration, which reflects whether a model’s predicted probabilities actually match observed event rates. The calibration slope fell from 0.894 to 0.431 across the same transition. A perfectly calibrated model has a slope of 1.0, so a slope of 0.431 indicates that the model was systematically overestimating risk in the newest cohort. Discrimination and calibration are distinct properties: a model can rank patients correctly while assigning probabilities that are wildly off. The Brier score, which combines both aspects into a single penalty, and decision curve analysis, which quantifies clinical net benefit at various risk thresholds, confirmed the deterioration from multiple angles.

Having documented the drift, the team then tested five updating strategies designed to keep the model current. These included recalibrating on temporally separated data, refitting on all accumulated history, weighting recent cases more heavily with a half-life scheme, using rolling windows that discard older data, and adjusting for calendar year. All analyses used ten imputed datasets to handle missing values, and uncertainty was quantified with 500 bootstrap resamples, a level of methodological rigor that lends weight to the comparisons. Refitting on all history achieved a mean AUC of 0.787 and a mean Brier score of 0.070, while the calendar year adjusted random forest and a rolling window random forest with a three-year window both achieved a mean AUC of 0.804.

The calendar year adjusted random forest emerged as one of the strongest performers overall. It achieved the lowest Brier score among the evaluated strategies, an observed-to-expected ratio closest to 1, indicating that its predicted event counts matched reality most closely, and slightly higher net benefit across most decision thresholds. In practical terms, this means the model not only ranked patients well but also produced risk estimates that clinicians could act on without systematically over- or under-treating. The finding suggests that explicitly accounting for the passage of calendar time, rather than treating all historical data as equally relevant, is an effective way to combat temporal drift.

The COVID-19 pandemic adds a fascinating natural experiment dimension to these results. The pandemic disrupted healthcare systems worldwide, altered infection patterns, changed healthcare-seeking behavior, and may have modified the immunological landscape of childhood inflammatory diseases. The sharp rise in IVIG resistance during the COVID era, from 7.0 percent to 13.9 percent, followed by a partial decline afterward, illustrates how dramatically the clinical environment can shift in a short window. A model trained on pre-pandemic data simply had no way of anticipating this change, which is exactly why static models fail when the world moves beneath them.

The implications extend well beyond Kawasaki disease. Prediction models are being embedded in electronic health records and clinical decision support systems at a rapid pace, yet few institutions have systematic processes for monitoring whether these tools still perform as advertised. This study demonstrates concretely that a model can lose accuracy within a few years and that time-aware updating strategies can recover much of the lost performance. The authors argue that ongoing performance monitoring and periodic model updating should be considered a routine part of long-term clinical implementation, not an afterthought. As artificial intelligence spreads through pediatric and adult medicine alike, this multicenter cohort offers a sobering and constructive lesson: a prediction model is not a finished product but a living tool that must be maintained, recalibrated, and refreshed as the patients and the world it serves continue to change.

Subject of Research: Temporal drift, calibration monitoring, and adaptive updating of an IVIG resistance prediction model in Kawasaki disease: a multicenter pediatric cohort study

Article Title: Temporal drift, calibration monitoring, and adaptive updating of an IVIG resistance prediction model in Kawasaki disease: a multicenter pediatric cohort study

Article References: Huang, H., He, Y., Zhang, J., Dong, J., Lin, F., Wang, C., Xu, Z., Chen, Q., Li, L., Zheng, X., Li, X., Hou, M., Liu, P., Tang, Q., & Lv, H. (2026). Temporal drift, calibration monitoring, and adaptive updating of an IVIG resistance prediction model in Kawasaki disease: a multicenter pediatric cohort study. BMC Medicine. https://doi.org/10.1186/s12916-026-05303-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05303-y

Keywords: Temporal, drift, calibration, monitoring, adaptive, updating, IVIG, resistance, prediction, model, Kawasaki, disease

ANEC is a severe, rapidly progressive neurological disorder that typically emerges in the wake of systemic infections, most often viral. It is characterized by a distinctive pattern of injury: bilateral lesions concentrated in the thalami, the paired structures deep within the brain that act as relay stations for sensory and motor signals. Unlike infectious encephalitis, in which a pathogen directly invades brain tissue, ANEC is thought to be driven by a dysregulated host immune response, sometimes described as a cytokine storm, in which inflammatory signaling molecules damage the small blood vessels of the brain and cause localized swelling, hemorrhage, and tissue death. The result is a condition that can evolve from fever and lethargy to seizures, coma, and profound neurological impairment within hours to days.

In the case described by the Iranian team, the diagnostic journey was far from straightforward. When the child was admitted to the tertiary center, laboratory testing revealed evidence of widespread systemic inflammation and multiorgan involvement. Her liver enzymes were markedly elevated, with aspartate aminotransferase measured at 130 units per liter and alanine aminotransferase at 210 units per liter, indicating hepatic injury. Lactate dehydrogenase, an enzyme released when cells are damaged or destroyed, was severely elevated at 6910 units per liter, a level consistent with extensive tissue breakdown. She also developed coagulopathy, a disorder of blood clotting, reflected in an international normalized ratio of 2.0 and a platelet count that had fallen to 51,000 per microliter. Together, these findings painted a picture of a body under systemic inflammatory assault.

One of the most instructive aspects of the case, the authors note, was the initial misdirection of the diagnostic workup. The child presented with severe hyperglycemia, an abnormally high blood sugar level, and metabolic acidosis, an accumulation of acid in the blood. These findings strongly suggested diabetic ketoacidosis, a well-known emergency in children with new-onset diabetes in which insulin deficiency leads to dangerous levels of blood glucose and acidic ketone bodies. However, in this patient the metabolic derangement was instead a manifestation of the overwhelming inflammatory process. This distinction matters enormously, because diabetic ketoacidosis and ANEC demand entirely different treatment strategies, and anchoring on the more familiar diagnosis can delay recognition of the underlying neuroimmune catastrophe.

Neuroimaging ultimately provided the key to the correct diagnosis. Computed tomography of the brain revealed characteristic bilateral thalamic hypodensities, regions of reduced density within both thalami that correspond to the edema and necrosis typical of ANEC. Notably, the team could not perform magnetic resonance imaging, which is normally the preferred modality for characterizing these lesions in greater detail, because the patient was too clinically unstable to undergo the prolonged scanning and monitoring that MRI requires. The case therefore highlights a practical reality of pediatric critical care: in the sickest children, clinicians may have to rely on CT findings alone, making familiarity with the CT signature of ANEC, symmetric thalamic involvement in the appropriate clinical context, an essential diagnostic skill.

As if the neurological injury were not enough, the clinical course was further complicated by concurrent fulminant myocarditis, a sudden and severe inflammation of the heart muscle. Echocardiography revealed an ejection fraction of just 20 percent, meaning the heart’s main pumping chamber was ejecting only a fifth of the blood it contained with each contraction, compared with a normal value of roughly 55 to 70 percent. This level of cardiac dysfunction constitutes a life-threatening emergency in its own right. The combination of ANEC and severe myocarditis in the same patient is particularly noteworthy, because both conditions are believed to share an inflammatory mechanism, and their co-occurrence suggests that the cytokine-mediated injury in this child was not confined to the central nervous system but swept through multiple organ systems at once.

Management of the patient required a multimodal approach coordinated across pediatric intensive care, cardiology, and neurology. The team deployed immunomodulatory therapy, including intravenous immunoglobulin, a preparation of pooled antibodies that can dampen harmful immune activity, and pulse methylprednisolone, high-dose corticosteroid therapy delivered in short bursts to suppress inflammation. Alongside these immune-targeted treatments, the clinicians provided neuroprotective care and intensive cardiovascular support to sustain perfusion of the brain and other organs while the heart recovered function. This combination reflects the current best available strategy for ANEC, which is grounded not in a single proven therapy but in early, aggressive control of the inflammatory response combined with meticulous supportive care.

Despite the aggressiveness of the intervention, the outcome was sobering. The child survived, but she sustained residual neurological deficits, including spasticity, a condition of abnormal muscle stiffness caused by damage to the motor pathways of the brain, and persistent abnormalities on electroencephalography, the recording of the brain’s electrical activity. These sequelae illustrate a central and frustrating truth about ANEC: even when the acute inflammatory storm is brought under control, the structural damage it inflicts on the thalami and surrounding structures can leave lasting functional impairment. Neurological outcomes in ANEC are highly variable, ranging from full recovery in milder cases to severe disability or death in the most fulminant presentations, and clinicians currently have limited ability to predict which trajectory an individual patient will follow.

The authors argue that their case carries several broader lessons for pediatric practice. First, recognition of the characteristic neuroimaging findings, particularly bilateral thalamic lesions in a child with fever and rapidly progressive encephalopathy, can substantially accelerate diagnosis and allow immunomodulatory therapy to begin before irreversible damage accumulates. Second, the metabolic disturbances seen in ANEC, including hyperglycemia and acidosis, can mimic more common conditions such as diabetic ketoacidosis, and clinicians should interpret these findings in the full clinical context rather than in isolation. Third, the involvement of extraneural organs, exemplified here by fulminant myocarditis and hepatic injury, means that ANEC should be understood as a multisystem inflammatory disorder rather than a purely neurological one, warranting a genuinely multidisciplinary treatment response.

Looking forward, the case report points to the gaps that remain in the field. The authors emphasize the need for improved diagnostic strategies that can identify ANEC earlier and more reliably, optimized therapeutic approaches built on stronger evidence than individual case experience currently allows, and long-term multidisciplinary rehabilitation programs to address the spasticity, cognitive impairment, and other deficits that survivors frequently carry. Because ANEC is rare, progress will likely depend on the accumulation and comparison of carefully documented cases such as this one, together with research into the immune mechanisms that drive the thalamic injury. For now, the message for clinicians is clear: in a child who deteriorates neurologically after an infection, especially when laboratory markers of systemic inflammation are extreme and other organs begin to fail, ANEC deserves a place high on the differential diagnosis, because time is the one variable that most strongly shapes the outcome.

Subject of Research: Acute necrotizing encephalopathy of childhood with concurrent severe myocarditis in a pediatric case report

Article Title: A challenging case of acute necrotizing encephalopathy of childhood with severe myocarditis

Article References: Hosseinzade, Z., Moshfegh, F., Javanbakht, M., & Javid, A. (2026). A challenging case of acute necrotizing encephalopathy of childhood with severe myocarditis. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07649-x

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07649-x

Keywords: acute necrotizing encephalopathy, ANEC, myocarditis, cytokine storm, thalamic lesions, pediatric critical care, neuroinflammation, immunomodulation, IVIG, methylprednisolone, neuroimaging, BMC Pediatrics

The scale of the problem is expanding rapidly. As cellular therapies and B-cell-depleting agents become standard care for hematologic malignancies, the number of patients with prolonged hypogammaglobulinemia, meaning abnormally low levels of immunoglobulin G, is expected to rise substantially. These patients suffer recurrent bacterial infections, frequent hospitalizations and a marked decline in health-related quality of life. The immune dysfunction is not uniform: B-cell-depleting drugs primarily damage humoral immunity, while stem cell transplantation and CAR-T therapy can produce broader defects that also impair cellular immune defenses and delay immune reconstitution for months or even years. Because diagnostic criteria developed for primary antibody deficiencies do not translate cleanly to these acquired conditions, clinicians must tailor immunoglobulin replacement to each patient’s infection history, immune status and treatment regimen.

The evidence that replacement therapy works is robust. Real-world data and clinical studies consistently show substantial reductions in infections, emergency department visits and hospital admissions once therapy begins. In the Ontario Immunoglobulin Treatment Case Registry, treatment was associated with an 82.6 percent reduction in annual infections, an 84.6 percent reduction in emergency department visits and an 83.3 percent reduction in hospitalizations. A Japanese retrospective cohort of patients with hematologic malignancy-associated hypogammaglobulinemia found that 20 percent subcutaneous immunoglobulin cut infection rates from 3.67 to 1.32 infections per patient-year. Post-marketing data for the subcutaneous product IgPro20 showed similar reductions in infections and serious bacterial events. Randomized trials and consensus guidelines support both routes for infection prevention in chronic lymphocytic leukemia, lymphoma and post-transplant populations.

The two delivery routes differ fundamentally in their pharmacokinetic behavior. Intravenous immunoglobulin is typically given every three to four weeks in a hospital or infusion center, producing a sharp peak in serum IgG followed by a gradual decline toward a trough before the next infusion. Subcutaneous immunoglobulin, by contrast, is administered more frequently, often weekly or biweekly, and sometimes monthly with facilitated formulations, yielding near-steady-state IgG concentrations with minimal peak-to-trough fluctuation. This smoother exposure profile matters clinically, because trough levels are a central pharmacokinetic goal of long-term management. Notably, a retrospective comparison of 131 patients with secondary antibody deficiency and 102 with primary antibody deficiency found that the secondary group achieved comparable reductions in infection burden despite receiving lower doses and reaching lower steady-state IgG trough concentrations, suggesting that dosing requirements differ between the two populations.

Safety profiles also diverge in clinically meaningful ways. Intravenous immunoglobulin carries a higher incidence of systemic adverse reactions, including headache, fever, nausea, thromboembolic events, aseptic meningitis, hemolysis and, less commonly, renal dysfunction or anaphylaxis. Systemic reactions occur in roughly 20 to 50 percent of patients and in 5 to 15 percent of infusions, although most are mild to moderate. Subcutaneous administration produces far fewer systemic events but more frequent local injection-site reactions such as erythema, swelling and rash, which are typically mild and self-limited. Facilitated subcutaneous immunoglobulin, which includes an added enzyme that allows larger volumes to be infused, may further improve tolerability while reducing hospital burden, according to emerging evidence reviewed by the authors.

Beyond infection control, the review highlights patient-reported outcomes as an increasingly important dimension of treatment success. Real-world studies show that subcutaneous therapy is associated with greater treatment convenience, improved autonomy and better quality-of-life scores, largely because patients can self-administer at home rather than traveling to infusion centers. Patients who switch from intravenous to subcutaneous treatment frequently report higher satisfaction and a reduced treatment burden. These gains in daily living are not merely cosmetic: they translate into measurable differences in how immunocompromised cancer survivors experience long-term supportive care.

Health economics reinforce the case for the subcutaneous route. A ten-year cost-utility analysis comparing hospital-based intravenous therapy with home-based subcutaneous therapy found that the subcutaneous approach yielded more quality-adjusted life years, 3.51 versus 3.07, at lower cumulative healthcare cost, making it the dominant strategy from a healthcare system perspective. Home-based administration reduces infusion-center utilization and hospital visits while maintaining clinical effectiveness, and registry data demonstrate durable treatment persistence during long-term subcutaneous therapy in routine practice. As global demand for plasma-derived immunoglobulin continues to climb, the review argues that responsible stewardship of this finite resource requires evidence-informed patient selection, periodic reassessment and timely discontinuation when immune recovery makes replacement unnecessary.

Guidance from major international bodies, including the American Academy of Allergy, Asthma, and Immunology, the British Committee for Standards in Hematology, the National Comprehensive Cancer Network and the European Society for Immunodeficiencies, supports either route for patients with documented hypogammaglobulinemia and recurrent or severe infections. The AAAAI recommends an individualized intravenous dosing range of 0.4 to 0.8 grams per kilogram every 28 days when clinically indicated. In practice, therapy is generally considered for patients with chronic lymphocytic leukemia or multiple myeloma whose IgG levels fall below roughly 400 to 500 milligrams per deciliter and who experience recurrent or severe infections despite appropriate antimicrobial management. Inadequate vaccine responses to diphtheria, tetanus or pneumococcal antigens can further support initiation in selected patients. For stem cell transplant recipients, routine prophylactic intravenous immunoglobulin is not recommended, but either route may be considered when IgG remains below 400 milligrams per deciliter with recurrent or severe infections. After CAR-T therapy, baseline immune assessment and individualized replacement strategies are increasingly advised.

The review emphasizes that there is no universally accepted IgG trough target for this population. Decisions to start, continue, modify or stop therapy should integrate serum IgG concentrations with infection history, underlying disease activity, ongoing immunosuppression and evidence of B-cell reconstitution rather than relying on a single numeric threshold. Monitoring should track infection frequency and severity, adverse events, treatment tolerability and, following B-cell-directed therapy, peripheral B-cell recovery assessed by flow cytometry when appropriate. Patients who remain infection-free and show immune recovery may interrupt or discontinue therapy, with reinitiation if infections recur, although validated biomarker thresholds for stopping treatment have not been established. The primary objective, the authors stress, is prevention of recurrent and severe infections, not achievement of a universal serum IgG number.

Significant gaps remain. Comparative prospective data on subcutaneous versus intravenous therapy in hematologic malignancy populations, particularly among CAR-T and transplant recipients, are scarce, and evidence on survival benefits is limited because most studies were not powered to detect mortality differences. Replacement therapy also addresses only humoral deficiency and cannot correct the broader cellular immune dysfunction that follows transplantation or CAR-T treatment. Several ongoing trials, including registries of facilitated subcutaneous immunoglobulin in multiple myeloma and a dedicated study of immunoglobulin for hypogammaglobulinemia after CAR-T therapy, should help refine dosing, monitoring and discontinuation criteria. For now, the message for clinicians is clear: both routes work, but for patients facing years of antibody replacement, the steadier pharmacokinetics, fewer systemic reactions and home-based convenience of the subcutaneous route make it an increasingly attractive first choice.

Subject of Research: Immunoglobulin replacement therapy via subcutaneous and intravenous routes for secondary immunodeficiency in hematologic malignancy patients

Article Title: Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG

Article References: Seaquist, E., Majapuro-Hirvonen, A., Van Wagoner, R., & Rutland, B. (2026). Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG. Frontiers in Hematology, 5, Article 1904290. https://doi.org/10.3389/frhem.2026.1904290

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1904290

Keywords: immunoglobulin replacement therapy, secondary immunodeficiency, hematologic malignancies, SCIG, IVIG, CAR-T therapy, hypogammaglobulinemia, immune reconstitution, infection prevention, pharmacokinetics, patient-reported outcomes, healthcare cost-effectiveness

The infant, who had been receiving chlorothiazide for the respiratory complications characteristic of bronchopulmonary dysplasia, presented at five months of chronological age, equivalent to two months of corrected age, with petechiae and mucosal bleeding. When bloodwork came back, the platelet count had plummeted to 7 × 10⁹ per liter, a level so low that spontaneous bleeding becomes a serious clinical concern. Normal platelet counts generally range well above 150 × 10⁹ per liter, meaning this infant had lost more than 95 percent of circulating platelets despite having tolerated the drug for over a quarter of a year.

What makes this case medically remarkable is its timing. Drug-induced immune thrombocytopenia, or DITP, is an antibody-mediated adverse effect that typically announces itself within days to weeks of drug exposure. The immune system, in susceptible individuals, generates antibodies that recognize a drug bound to platelet surfaces, marking the platelets for destruction by the spleen. In this infant, however, the reaction emerged only after more than three months of continuous therapy, a delayed onset that could easily have misled clinicians toward other diagnoses and delayed the correct intervention.

The diagnostic workup was exhaustive. Because isolated thrombocytopenia in an infant carries a long differential diagnosis, the clinical team systematically excluded infectious causes, including congenital and acquired viral infections, as well as malignant and consumptive processes such as disseminated intravascular coagulation. Neonatal alloimmune thrombocytopenia, in which maternal antibodies cross the placenta and attack fetal platelets, was also considered and ruled out. A bone marrow examination showed no evidence of leukemia or aplastic failure; instead, the findings were compatible with peripheral platelet destruction, the hallmark of an immune-mediated process occurring in the bloodstream rather than a failure of platelet production in the marrow.

The definitive answer came from a specialized laboratory technique known as monoclonal antibody immobilization of platelet antigens, or MAIPA. This assay can detect antibodies that bind to platelet glycoproteins only in the presence of a specific drug. In this case, the testing confirmed chlorothiazide-dependent antibodies directed against glycoprotein IIb/IIIa, the integrin receptor that platelets use to aggregate and form clots. The demonstration of drug-dependent anti-GPIIb/IIIa antibodies transformed the case from a diagnostic puzzle into a clear example of chlorothiazide-induced immune thrombocytopenia, an entity almost never reported in infants receiving prolonged diuretic therapy.

Treatment followed the established logic of immune-mediated platelet destruction. The offending drug was discontinued immediately, and intravenous immunoglobulin, or IVIG, was administered. IVIG works through several mechanisms, including saturating the Fc receptors on macrophages in the spleen so that antibody-coated platelets escape destruction. The response was rapid and decisive: the infant’s platelet count returned to normal within one week, confirming that removing the drug and damping the immune destruction was sufficient to reverse the condition without further intervention.

Long-term follow-up added reassuring context to an alarming episode. At six months of corrected age, the child maintained sustained normal platelet counts, showed appropriate growth at 7.8 kilograms, placing the infant at the 30th percentile, and demonstrated normal neurodevelopment on Ages and Stages Questionnaire screening. No further bleeding or infectious complications were documented. The complete recovery underscores that, once the trigger is identified and removed, drug-induced immune thrombocytopenia in infancy can resolve fully without lasting consequences.

The clinical lesson embedded in this case is one of vigilance rather than alarm. Chlorothiazide remains a cornerstone of therapy for infants with bronchopulmonary dysplasia, where it helps reduce pulmonary edema and improve respiratory mechanics, and serious adverse reactions remain exceedingly rare. But the authors argue that the rarity of the reaction is precisely why it can be overlooked. When a preterm infant on prolonged thiazide therapy presents with isolated thrombocytopenia, medication-related causes deserve a place near the top of the differential, even when the drug has been tolerated for months without incident.

The case also highlights the value of modern immunological diagnostics in pediatrics. Without MAIPA testing, the connection between chlorothiazide and the platelet destruction would have remained presumptive, resting on temporal association and the exclusion of alternatives. By confirming drug-dependent antibodies against a specific platelet glycoprotein, the clinicians converted suspicion into proof, a distinction that matters both for the individual patient, who can now avoid the drug permanently, and for the broader medical record, where confirmed cases inform future prescribing decisions and pharmacovigilance databases.

For the community of neonatologists and pediatric hematologists who care for the growing population of surviving extremely preterm infants, the report supports a simple but consequential practice change: routine hematologic monitoring during prolonged thiazide therapy. The infant at the center of this case survived a platelet count that, unrecognized, could have led to catastrophic hemorrhage. That the outcome was instead a full recovery with normal development reflects both the resilience of the child and the diagnostic persistence of the clinical team, and it offers a cautionary, ultimately hopeful, data point for a rare reaction hiding inside a very common prescription.

Subject of Research: Chlorothiazide-induced immune thrombocytopenia in a former preterm infant with bronchopulmonary dysplasia

Article Title: Severe, delayed-onset thrombocytopenia after prolonged chlorothiazide use in a former preterm infant with bronchopulmonary dysplasia: a case report

Article References: Adi, M., Ishmuradov, B., Husanov, S., Kuziev, O., & Ashraf, A. (2026). Severe, delayed-onset thrombocytopenia after prolonged chlorothiazide use in a former preterm infant with bronchopulmonary dysplasia: a case report. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07742-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07742-1

Keywords: drug-induced immune thrombocytopenia, chlorothiazide, bronchopulmonary dysplasia, preterm infant, thrombocytopenia, diuretics, MAIPA, platelet antibodies, adverse drug reaction, neonatology, IVIG, pediatrics